David Reardon

David Reardon leads clinical investigations of immunotherapy for glioblastoma and brain tumors. His research has conducted pivotal trials of anti-PD-1 therapy in newly diagnosed and recurrent GBM, including the CheckMate 143 and related studies that helped characterize the immunosuppressive tumor microenvironment as a major barrier to checkpoint inhibitor efficacy in GBM. He has investigated combinatorial immunotherapy strategies including anti-PD-1 plus anti-CTLA-4, IL-2, and vaccines to overcome GBM immune resistance. His clinical leadership in neuro-oncology immunotherapy has advanced the field's understanding of why GBM presents unique challenges to immunotherapy and motivated novel approaches to improve outcomes.